{
    "name": "cisatracurium",
    "comment": "Rx",
    "other_names": [
        "Nimbex"
    ],
    "classes": [
        "Neuromuscular Blockers",
        "Nondepolarizing"
    ],
    "source": "https://reference.medscape.com/drug/nimbex-cisatracurium-343104",
    "pregnancy": {
        "common": [
            "There are no adequate and well-controlled studies in pregnant women",
            "The 10 mL multiple-dose vials contain the preservative benzyl alcohol; therefore, if therapy is needed during pregnancy, consider using a benzyl alcohol-free formulation (ie, 5 mL and 20 mL single-dose vials)",
            "Because benzyl alcohol is rapidly metabolized by a pregnant woman, benzyl alcohol exposure in the fetus is unlikely; however, adverse reactions have occurred in premature neonates and low birth weight infants who received intravenously administered benzyl alcohol-containing drugs",
            "There are no available clinical trial data on cisatracurium use in pregnancy to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Animal studies conducted in rats administered cisatracurium besylate during organogenesis (gestational day 6 to 15) found no evidence of fetal harm at 0.8 times (ventilated rats) the exposure from a human starting IV bolus dose of 0.2 mg/kg"
                ]
            },
            {
                "type": "Labor or delivery",
                "description": [
                    "The action of neuromuscular blocking agents may be enhanced by magnesium salts administered for management of preeclampsia or eclampsia of pregnancy"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "The 10 mL multiple-dose vials contain the preservative benzyl alcohol; if therapy is needed during lactation, consider using a benzyl alcohol-free formulation (ie, 5 mL and 20 mL single-dose vials)",
            "Because benzyl alcohol is rapidly metabolized by a lactating woman, benzyl alcohol exposure in the breastfed infant is unlikely; however, adverse reactions have occurred in premature neonates and low birth weight infants who received intravenously administered benzyl alcohol-containing drugs",
            "There are no data on presence of the drug in human milk, effects on breastfed child, or on milk production; developmental and health benefits of breastfeeding should be considered along with mother's clinical need for therapy and any potential adverse effects on breastfed child from treatment or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to cisatracurium (or benzyl alcohol if 10 mL vial is used)",
                "Use of 10 mL vial in pediatric patients <1 month of age and low birth-weight infants (contains benzyl alcohol)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Laudanosine, an active metabolite, reported to cause seizures in animals; patients with renal or hepatic impairment receiving extended therapy may be at higher risk of seizures; monitor level of neuromuscular blockade during long-term administration to limit exposure to toxic metabolites",
                "Severe anaphylactic reactions to neuromuscular blocking agents have been reported; some cases have been life threatening and fatal; take necessary precautions, such as the immediate availability of appropriate emergency treatment",
                "Confirm proper selection of intended product and avoid confusion with other injectable solutions that are present in critical care and other clinical settings; ensure that the intended dose is clearly labeled and communicated when another healthcare provider is administered",
                "Neuromuscular blockade in the conscious patient can lead to distress; use drug in presence of appropriate sedation or general anesthesia and monitor patients to ensure level of anesthesia is adequate",
                "The 20-mL vials contain no preservatives and are intended only for IV infusion in a single patient in the ICU; not to be used as a multidose vial for different patients because there is a higher risk of infection",
                "Not studied in malignancy hyperthermia (MH)-susceptible patients; MH can develop in absence of established triggering agents; prepare to recognize and treat MH in any patient undergoing general anesthesia"
            ],
            "specific": [
                {
                    "type": "Residual paralysis",
                    "description": [
                        "Residual paralysis has been associated with therapy",
                        "Lower maximum initial bolus in patients at higher risk of residual paralysis (eg, patients with neuromuscular diseases, carcinomatosis)",
                        "Extubation is recommended only after patient has recovered sufficiently from neuromuscular blockade",
                        "Consider use of a reversal agent especially in cases where residual paralysis is more likely to occur"
                    ]
                },
                {
                    "type": "Risk of serious adverse reactions in infants due to benzyl alcohol",
                    "description": [
                        "Serious and fatal adverse reactions including “gasping syndrome” can occur in neonates and infants treated with benzyl alcohol-containing drugs",
                        "Multidose 10-mL vials contains benzyl alcohol; not applicable in single-dose 5-mL or 20-mL vials",
                        "“Gasping syndrome” is characterized by CNS depression, metabolic acidosis, and gasping respirations",
                        "Use of 10-mL vials is contraindicated in infants <1 month or have low birth-weight"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Succinylcholine",
                        "Use of succinylcholine before cisatracurium administration may decrease onset of maximum neuromuscular blockade but has no effect on duration of neuromuscular blockade",
                        "Inhalational anesthetics",
                        "Administration of inhalational anesthetics with nitrous oxide/oxygen for >30 min to achieve 1.25 minimum alveolar concentration may prolong duration of action of initial and maintenance doses; may potentiate the neuromuscular blockade",
                        "Potentiation of neuromuscular blockade",
                        "Certain drugs may enhance neuromuscular blocking action including inhalational anesthetics, antibiotics, magnesium salts, lithium, local anesthetics, procainamide and quinidine",
                        "Additionally, acid-base and/or serum electrolyte abnormalities may potentiate taction of neuromuscular blocking agents",
                        "Use peripheral nerve stimulation; monitor clinical signs of neuromuscular blockade and adjust dose, if necessary",
                        "Resistance to neuromuscular blockade with certain drugs ",
                        "Shorter durations of neuromuscular block may occur; may require higher infusion rates in patients chronically administered phenytoin or carbamazepine",
                        "Use peripheral nerve stimulation and monitor the clinical signs of neuromuscular blockade "
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "amikacin",
            "description": {
                "common": "amikacin increases effects of cisatracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of apnea."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amphotericin B deoxycholate",
            "description": {
                "common": "amphotericin B deoxycholate increases effects of cisatracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "benzhydrocodone/acetaminophen",
            "description": {
                "common": "benzhydrocodone/acetaminophen, cisatracurium.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "capreomycin",
            "description": {
                "common": "capreomycin increases effects of cisatracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clindamycin",
            "description": {
                "common": "clindamycin increases effects of cisatracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "colistin",
            "description": {
                "common": "cisatracurium increases effects of colistin by pharmacodynamic synergism. Avoid or Use Alternate Drug. Potentiation of neuromuscular blockade; risk of respiratory arrest."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "demeclocycline",
            "description": {
                "common": "demeclocycline increases effects of cisatracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "doxycycline",
            "description": {
                "common": "doxycycline increases effects of cisatracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fentanyl",
            "description": {
                "common": "fentanyl, cisatracurium.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fentanyl intranasal",
            "description": {
                "common": "fentanyl intranasal, cisatracurium.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fentanyl transdermal",
            "description": {
                "common": "fentanyl transdermal, cisatracurium.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fentanyl transmucosal",
            "description": {
                "common": "fentanyl transmucosal, cisatracurium.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "gentamicin",
            "description": {
                "common": "gentamicin increases effects of cisatracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of apnea."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydrocodone",
            "description": {
                "common": "hydrocodone, cisatracurium.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lincomycin",
            "description": {
                "common": "lincomycin increases effects of cisatracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "minocycline",
            "description": {
                "common": "minocycline increases effects of cisatracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "neomycin PO",
            "description": {
                "common": "neomycin PO increases effects of cisatracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of apnea."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "omadacycline",
            "description": {
                "common": "omadacycline increases effects of cisatracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxytetracycline",
            "description": {
                "common": "oxytetracycline increases effects of cisatracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "paromomycin",
            "description": {
                "common": "paromomycin increases effects of cisatracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of apnea."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "polymyxin B",
            "description": {
                "common": "polymyxin B increases effects of cisatracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of resp. depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pramlintide",
            "description": {
                "common": "pramlintide, cisatracurium.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "quinine",
            "description": {
                "common": "quinine increases effects of cisatracurium by pharmacodynamic synergism. Contraindicated. Risk of resp. depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sarecycline",
            "description": {
                "common": "sarecycline increases effects of cisatracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "streptomycin",
            "description": {
                "common": "streptomycin increases effects of cisatracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of apnea."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sufentanil SL",
            "description": {
                "common": "sufentanil SL, cisatracurium.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may result in hypotension, profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tetracycline",
            "description": {
                "common": "tetracycline increases effects of cisatracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tobramycin",
            "description": {
                "common": "tobramycin increases effects of cisatracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of apnea."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "valerian",
            "description": {
                "common": "valerian and cisatracurium both increase  sedation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "abobotulinumtoxinA",
            "description": {
                "common": "cisatracurium increases effects of abobotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Neuromuscular blockers may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aclidinium",
            "description": {
                "common": "cisatracurium and aclidinium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amitriptyline",
            "description": {
                "common": "cisatracurium and amitriptyline both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amoxapine",
            "description": {
                "common": "cisatracurium and amoxapine both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "anticholinergic/sedative combos",
            "description": {
                "common": "anticholinergic/sedative combos and cisatracurium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "cisatracurium decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atracurium",
            "description": {
                "common": "atracurium and cisatracurium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atropine",
            "description": {
                "common": "atropine and cisatracurium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atropine IV/IM",
            "description": {
                "common": "atropine IV/IM and cisatracurium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belladonna alkaloids",
            "description": {
                "common": "belladonna alkaloids and cisatracurium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belladonna and opium",
            "description": {
                "common": "cisatracurium and belladonna and opium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benperidol",
            "description": {
                "common": "cisatracurium decreases levels of benperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betamethasone",
            "description": {
                "common": "cisatracurium, betamethasone. Other (see comment). Use Caution/Monitor. \nComment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bethanechol",
            "description": {
                "common": "bethanechol increases and cisatracurium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buprenorphine, long-acting injection",
            "description": {
                "common": "cisatracurium increases toxicity of buprenorphine, long-acting injection by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of buprenorphine and benzodiazepines or other CNS depressants increases risk of adverse reactions including overdose, respiratory depression, and death. Cessation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher level of care for tapering CNS depressants may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbachol",
            "description": {
                "common": "carbachol increases and cisatracurium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cevimeline",
            "description": {
                "common": "cevimeline increases and cisatracurium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpromazine",
            "description": {
                "common": "cisatracurium decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clomipramine",
            "description": {
                "common": "cisatracurium and clomipramine both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clozapine",
            "description": {
                "common": "cisatracurium decreases levels of clozapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "corticotropin",
            "description": {
                "common": "cisatracurium, corticotropin. Other (see comment). Use Caution/Monitor. \nComment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cortisone",
            "description": {
                "common": "cisatracurium, cortisone. Other (see comment). Use Caution/Monitor. \nComment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclizine",
            "description": {
                "common": "cisatracurium and cyclizine both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclobenzaprine",
            "description": {
                "common": "cisatracurium and cyclobenzaprine both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "darifenacin",
            "description": {
                "common": "cisatracurium and darifenacin both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deflazacort",
            "description": {
                "common": "cisatracurium, deflazacort. Other (see comment). Use Caution/Monitor. \nComment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "cisatracurium, dexamethasone. Other (see comment). Use Caution/Monitor. \nComment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dicyclomine",
            "description": {
                "common": "cisatracurium and dicyclomine both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diphenhydramine",
            "description": {
                "common": "cisatracurium and diphenhydramine both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "donepezil",
            "description": {
                "common": "donepezil increases and cisatracurium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "donepezil transdermal",
            "description": {
                "common": "donepezil transdermal and cisatracurium both increase  pharmacodynamic synergism. Use Caution/Monitor. Donepezil transdermal, a cholinesterase inhibitor, may potentiate the effects on muscle relacation during anesthesia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dosulepin",
            "description": {
                "common": "cisatracurium and dosulepin both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxapram",
            "description": {
                "common": "doxapram decreases effects of cisatracurium by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxepin",
            "description": {
                "common": "cisatracurium and doxepin both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "droperidol",
            "description": {
                "common": "cisatracurium decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "echothiophate iodide",
            "description": {
                "common": "echothiophate iodide increases and cisatracurium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fesoterodine",
            "description": {
                "common": "cisatracurium and fesoterodine both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flavoxate",
            "description": {
                "common": "cisatracurium and flavoxate both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fludrocortisone",
            "description": {
                "common": "cisatracurium, fludrocortisone. Other (see comment). Use Caution/Monitor. \nComment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluphenazine",
            "description": {
                "common": "cisatracurium decreases levels of fluphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin decreases effects of cisatracurium by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Monitor closely for more rapid recovery from neuromuscular blockade than expected; infusion rate requirements may be higher."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "galantamine",
            "description": {
                "common": "galantamine increases and cisatracurium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glycopyrrolate inhaled",
            "description": {
                "common": "cisatracurium and glycopyrrolate inhaled both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "haloperidol",
            "description": {
                "common": "cisatracurium decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "henbane",
            "description": {
                "common": "cisatracurium and henbane both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "homatropine",
            "description": {
                "common": "cisatracurium and homatropine both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "huperzine A",
            "description": {
                "common": "huperzine A increases and cisatracurium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrocortisone",
            "description": {
                "common": "cisatracurium, hydrocortisone. Other (see comment). Use Caution/Monitor. \nComment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hyoscyamine",
            "description": {
                "common": "cisatracurium and hyoscyamine both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hyoscyamine spray",
            "description": {
                "common": "cisatracurium and hyoscyamine spray both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iloperidone",
            "description": {
                "common": "cisatracurium decreases levels of iloperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imipramine",
            "description": {
                "common": "cisatracurium and imipramine both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ipratropium",
            "description": {
                "common": "cisatracurium and ipratropium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lofepramine",
            "description": {
                "common": "cisatracurium and lofepramine both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loxapine",
            "description": {
                "common": "cisatracurium decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loxapine inhaled",
            "description": {
                "common": "loxapine inhaled increases effects of cisatracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "magnesium sulfate",
            "description": {
                "common": "magnesium sulfate increases effects of cisatracurium by pharmacodynamic synergism. Use Caution/Monitor. Interaction occurs with parenteral magnesium."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "magnesium supplement",
            "description": {
                "common": "magnesium supplement, cisatracurium.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maprotiline",
            "description": {
                "common": "cisatracurium and maprotiline both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meclizine",
            "description": {
                "common": "cisatracurium and meclizine both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methscopolamine",
            "description": {
                "common": "cisatracurium and methscopolamine both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "cisatracurium, methylprednisolone. Other (see comment). Use Caution/Monitor. \nComment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "neostigmine",
            "description": {
                "common": "neostigmine increases and cisatracurium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nortriptyline",
            "description": {
                "common": "cisatracurium and nortriptyline both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olanzapine",
            "description": {
                "common": "cisatracurium decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oliceridine",
            "description": {
                "common": "oliceridine, cisatracurium.\nEither increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "onabotulinumtoxinA",
            "description": {
                "common": "onabotulinumtoxinA and cisatracurium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "orphenadrine",
            "description": {
                "common": "cisatracurium and orphenadrine both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxybutynin",
            "description": {
                "common": "cisatracurium and oxybutynin both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxybutynin topical",
            "description": {
                "common": "cisatracurium and oxybutynin topical both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxybutynin transdermal",
            "description": {
                "common": "cisatracurium and oxybutynin transdermal both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxycodone",
            "description": {
                "common": "oxycodone increases effects of cisatracurium by unspecified interaction mechanism. Modify Therapy/Monitor Closely. Oxycodone may enhance the neuromuscular blocking action of true skeletal muscle relaxants and produce an increased degree of respiratory depression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paliperidone",
            "description": {
                "common": "cisatracurium decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pancuronium",
            "description": {
                "common": "cisatracurium and pancuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "perphenazine",
            "description": {
                "common": "cisatracurium decreases levels of perphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin decreases effects of cisatracurium by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Monitor closely for more rapid recovery from neuromuscular blockade than expected; infusion rate requirements may be higher."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "physostigmine",
            "description": {
                "common": "physostigmine increases and cisatracurium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pilocarpine",
            "description": {
                "common": "pilocarpine increases and cisatracurium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pimozide",
            "description": {
                "common": "cisatracurium decreases levels of pimozide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pralidoxime",
            "description": {
                "common": "cisatracurium and pralidoxime both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prednisolone",
            "description": {
                "common": "cisatracurium, prednisolone. Other (see comment). Use Caution/Monitor. \nComment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prednisone",
            "description": {
                "common": "cisatracurium, prednisone. Other (see comment). Use Caution/Monitor. \nComment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prochlorperazine",
            "description": {
                "common": "cisatracurium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "promethazine",
            "description": {
                "common": "cisatracurium decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propantheline",
            "description": {
                "common": "cisatracurium and propantheline both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "protriptyline",
            "description": {
                "common": "cisatracurium and protriptyline both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pyridostigmine",
            "description": {
                "common": "pyridostigmine increases and cisatracurium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quetiapine",
            "description": {
                "common": "cisatracurium decreases levels of quetiapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rapacuronium",
            "description": {
                "common": "cisatracurium and rapacuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "risperidone",
            "description": {
                "common": "cisatracurium decreases levels of risperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rocuronium",
            "description": {
                "common": "cisatracurium and rocuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "scopolamine",
            "description": {
                "common": "cisatracurium and scopolamine both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sevoflurane",
            "description": {
                "common": "sevoflurane increases levels of cisatracurium by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/?magnesium sulfate/potassium chloride",
            "description": {
                "common": "sodium sulfate/?magnesium sulfate/potassium chloride increases effects of cisatracurium by Other (see comment). Use Caution/Monitor. \nComment: Magnesium may potentiate the effects of the neuromuscular blocking agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/potassium sulfate/magnesium sulfate",
            "description": {
                "common": "sodium sulfate/potassium sulfate/magnesium sulfate increases effects of cisatracurium by Other (see comment). Use Caution/Monitor. \nComment: Magnesium may potentiate the effects of the neuromuscular blocking agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "solifenacin",
            "description": {
                "common": "cisatracurium and solifenacin both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "succinylcholine",
            "description": {
                "common": "succinylcholine increases and cisatracurium decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thioridazine",
            "description": {
                "common": "cisatracurium decreases levels of thioridazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thiothixene",
            "description": {
                "common": "cisatracurium decreases levels of thiothixene by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tiotropium",
            "description": {
                "common": "cisatracurium and tiotropium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tobramycin inhaled",
            "description": {
                "common": "tobramycin inhaled increases effects of cisatracurium by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Aminoglycosides may aggravate muscle weakness because of a curare-like effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolterodine",
            "description": {
                "common": "cisatracurium and tolterodine both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triamcinolone acetonide injectable suspension",
            "description": {
                "common": "cisatracurium, triamcinolone acetonide injectable suspension. Other (see comment). Use Caution/Monitor. \nComment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trifluoperazine",
            "description": {
                "common": "cisatracurium decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trimipramine",
            "description": {
                "common": "cisatracurium and trimipramine both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trospium chloride",
            "description": {
                "common": "cisatracurium and trospium chloride both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vecuronium",
            "description": {
                "common": "cisatracurium and vecuronium both decrease  cholinergic effects/transmission. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ziprasidone",
            "description": {
                "common": "cisatracurium decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zotepine",
            "description": {
                "common": "cisatracurium decreases levels of zotepine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetazolamide",
            "description": {
                "common": "acetazolamide decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amlodipine",
            "description": {
                "common": "amlodipine increases effects of cisatracurium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clevidipine",
            "description": {
                "common": "clevidipine increases effects of cisatracurium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clonazepam",
            "description": {
                "common": "clonazepam decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "desipramine",
            "description": {
                "common": "cisatracurium and desipramine both decrease  cholinergic effects/transmission. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diazepam",
            "description": {
                "common": "diazepam decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diltiazem",
            "description": {
                "common": "diltiazem increases effects of cisatracurium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dimenhydrinate",
            "description": {
                "common": "dimenhydrinate increases toxicity of cisatracurium by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "donepezil",
            "description": {
                "common": "donepezil decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "eslicarbazepine acetate",
            "description": {
                "common": "eslicarbazepine acetate decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethosuximide",
            "description": {
                "common": "ethosuximide decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "felbamate",
            "description": {
                "common": "felbamate decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "felodipine",
            "description": {
                "common": "felodipine increases effects of cisatracurium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "gabapentin",
            "description": {
                "common": "gabapentin decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "gabapentin enacarbil",
            "description": {
                "common": "gabapentin enacarbil decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "galantamine",
            "description": {
                "common": "galantamine decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "isradipine",
            "description": {
                "common": "isradipine increases effects of cisatracurium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lacosamide",
            "description": {
                "common": "lacosamide decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lamotrigine",
            "description": {
                "common": "lamotrigine decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "levetiracetam",
            "description": {
                "common": "levetiracetam decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lithium",
            "description": {
                "common": "lithium increases effects of cisatracurium by unknown mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lorazepam",
            "description": {
                "common": "lorazepam decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methsuximide",
            "description": {
                "common": "methsuximide decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nicardipine",
            "description": {
                "common": "nicardipine increases effects of cisatracurium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nifedipine",
            "description": {
                "common": "nifedipine increases effects of cisatracurium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nisoldipine",
            "description": {
                "common": "nisoldipine increases effects of cisatracurium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxcarbazepine",
            "description": {
                "common": "oxcarbazepine decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "quinidine",
            "description": {
                "common": "quinidine increases effects of cisatracurium by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rufinamide",
            "description": {
                "common": "rufinamide decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "thiamine",
            "description": {
                "common": "thiamine increases effects of cisatracurium by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tiagabine",
            "description": {
                "common": "tiagabine decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "topiramate",
            "description": {
                "common": "topiramate decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "trazodone",
            "description": {
                "common": "cisatracurium and trazodone both decrease  cholinergic effects/transmission. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "valproic acid",
            "description": {
                "common": "valproic acid decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "verapamil",
            "description": {
                "common": "verapamil increases effects of cisatracurium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "zonisamide",
            "description": {
                "common": "zonisamide decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Bronchospasm",
            "percent": null
        },
        {
            "name": "Bradycardia",
            "percent": null
        },
        {
            "name": "Flushing",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Myositis ossificans",
            "percent": null
        },
        {
            "name": "Hypotension",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Anaphylaxis",
            "percent": null
        },
        {
            "name": "Histamine release",
            "percent": null
        },
        {
            "name": "Prolonged neuromuscular block",
            "percent": null
        },
        {
            "name": "Muscle weakness",
            "percent": null
        },
        {
            "name": "myopathy",
            "percent": null
        }
    ]
}